Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Shin Nippon Biomedical Laboratories Ltd (2395)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,506.0 +22.0    +1.49%
26/04 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3379950003 
  • Volume: 186,500
  • Bid/Ask: 1,502.0 / 1,506.0
  • Day's Range: 1,473.0 - 1,516.0
Shin Nippon Biomed Lab 1,506.0 +22.0 +1.49%

Shin Nippon Biomedical Laboratories Ltd Company Profile

 
Get an in-depth profile of Shin Nippon Biomedical Laboratories Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1360

Equity Type

ORD

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of vaccines and therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines. Further, the company is involved in the operates geothermal power generation; operates hotel accommodation facilities; and wellbeing businesses, as well as provides cleaning, clerical work, and welfare services. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.

Contact Information

Address 2438 Miyanoura-cho
Kagoshima, 891-1394
Japan
Phone 81 9 9294 3389
Fax 81 9 9294 3619

Top Executives

Name Age Since Title
Hideshi Tsusaki - - Senior MD & Director
Shinji Nitanda 55 2010 Senior MD of Corporate Development & Corporate Tax Administration and Director
Ryoichi Nagata 65 1991 Chairman, CEO, President, Head of Fisheries Business & CHO
Kyomi Nagatoshi - - Managing Executive Officer, Head of General Affairs & Human Resources and Director
Takakiyo Ashino 58 2019 Auditor
Yoshikazu Shigehisa 71 2019 Auditor
Masakazu Suda 62 2020 Full-Time Auditor
Shinichi Fukumoto 65 2015 Independent Outside Director
Keiko Totani 59 2021 Independent Outside Director
Tsuyoshi Hanada 65 2020 Independent Outside Director
Takashi Yamashita 67 2015 Independent Outside Director
Ken Takanashi 59 2002 Executive VP of Group Corporate Management & Global Business & Director
Hideshi Tsusaki 57 2014 Senior MD, President of Non-Clinical & Global Business Development and Director
Ichiro Nagata 39 2020 Executive VP, Head of CRO Business, Head of Hospitality Business & Director
Eishi Tsunozaki 57 2014 Senior MD & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2395 Comments

Write your thoughts about Shin Nippon Biomedical Laboratories Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email